MNPR

Monopar Therapeutics Inc.

117.61 USD

Last updated Sep 4, 21:06 UTC

Yesterday HIGH

$121.02

Yesterday LOW

$115.3

52w HIGH

$124.42

52w LOW

$32.77

EPS

-0.62

PE

-189.69

Next Earnings

Nov 12, 2026

Overview News Insider Transactions Government Trades Fundamentals

Monopar Therapeutics Inc. stock is down -1.36% since 30 days ago. The next earnings date is Nov 12, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 42.86% of the previous 6 September’s closed higher than August. 67% of analysts rate it a buy.

Benzinga Newsdesk

Tue Jun 30, 2026

Monopar Says FDA Grants Rare Pediatric Disease Designation To ALXN1840, Late-Stage Candidate For Treatment Of Wilson Disease

Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced
Benzinga Newsdesk

Tue Jun 30, 2026

BTIG Maintains Buy on Monopar Therapeutics, Raises Price Target to $117

BTIG analyst Jeet Mukherjee maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and raises the price target from $104 to $117.
Benzinga Newsdesk

Mon Jun 29, 2026

Monopar Therapeutics shares are trading higher after HC Wainwright & Co. reiterated its Buy rating on the stock and maintained a $105 price target.
Benzinga Newsdesk

Mon Jun 29, 2026

HC Wainwright & Co. Reiterates Buy on Monopar Therapeutics, Maintains $105 Price Target

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Monopar Therapeutics (NASDAQ:MNPR) with a Buy and maintains $105 price target.
Benzinga Newsdesk

Fri Jun 26, 2026

Monopar Therapeutics To Present New Analyses From Phase 3 FoCus Randomized Clinical Trial Of ALXN1840 At EAN 2026.

Key findings presented at EAN 2026:In the subset of patients with neurologic symptoms at baseline from the 2:1 randomized Phase 3 FoCus clinical trial (NCT03403205; n=207), ALXN1840 demonstrated improved outcomes
Benzinga Insights

Tue Jun 23, 2026

12 Health Care Stocks Moving In Tuesday's Intraday Session

Gainers Aditxt (NASDAQ:ADTX) shares increased by 151.6% to $0.05 during Tuesday's regular session. Atlantic International (NASDAQ:ATLN) stock rose 143.31% to $1.07. The market value of their outstanding shares is
Benzinga Newsdesk

Wed May 20, 2026

Monopar Therapeutics shares are trading higher after the company announced it published a peer-reviewed manuscript entitled "Effect of Tiomolibdate Choline on Copper Balance in Patients with Wilson Disease: an Open-label Phase 2 Trial." in the Hepatology Communications
Benzinga Newsdesk

Tue May 19, 2026

Monopar Therapeutics Publishes Phase 2 Study Demonstrating ALXN1840 Improves Copper Balance In Patients With Wilson Disease

Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced
Benzinga Newsdesk

Thu May 14, 2026

Monopar Therapeutics Q1 EPS $(0.46) Beats $(0.83) Estimate
Benzinga Newsdesk

Mon Apr 20, 2026

Reported Sunday, Monopar Presents Phase 3 Data At AAN 2026 Showing ALXN1840 Delivers Greater Neurologic Benefit And Lower Worsening Rates Versus Standard Of Care In Wilson Disease

Barclays

Thu Aug 13, 16:21

buy

confirm
Cantor Fitzgerald

Thu Aug 13, 13:52

hold

downgrade
BTIG

Wed Aug 12, 21:46

buy

confirm

Advanced Data Unlock

Kim Tsuchimoto, Director

Wed Aug 26, 2026

MNPR Recent Insider Trades and Stock Chart

4,090 shares sold
Kim Tsuchimoto, Director

Wed Aug 26, 2026

MNPR Recent Insider Trades and Stock Chart

4,090 shares sold
PATRICE RIOUX, Insider

Wed Aug 26, 2026

MNPR Recent Insider Trades and Stock Chart

1 shares sold
Raymond Anderson, Director

Tue Aug 25, 2026

MNPR Recent Insider Trades and Stock Chart

3,142 shares sold
Raymond Anderson, Director

Tue Aug 25, 2026

MNPR Recent Insider Trades and Stock Chart

3,142 shares sold